HLB, an international biopharmaceutical company, submitted a new drug application (NDA) for its Rivoceranib liver cancer drug to the U.S. Food and Drug Administration (FDA) on Tuesday. If successful, it would become the first Korean biotechnology company to win a new drug approval in the U.S., the company said Thursday.
A new drug application has been submitted to the FDA for the combination of rivoceranib and camrelizumab as a first-line treatment option for patients with unresectable hepatocellular carcinoma.
A new research paper was published in Oncotarget's Volume 13 on December 6, 2022, entitled, "Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients."
Plasma GH Predicts Response to Atezolizumab & Bevacizumab in HCC miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.